Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can more Hands-On therapy and home devices help children with SMA?

NCT ID NCT06419322

Symptom relief Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers at the University of Oxford are studying an optimized rehabilitation program for children with spinal muscular atrophy (SMA) who are already on a stable disease-modifying treatment. The program adds goal-oriented rehabilitation, hands-on physiotherapy sessions, and a home rehabilitation device to the current standard of care. The study aims to see whether families find the program acceptable and feasible, and whether it is safe and effective compared to the rehabilitation children currently receive. Fourteen children aged 1 to 10 will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an optimized rehabilitation program combining goal-oriented therapy, hands-on physiotherapy, and a home rehabilitation device
What this could lead to
If it works, this could give families a clearer, more supportive way to deliver rehabilitation at home and ease the burden on parents who currently manage therapy alone.
What could go wrong
This is a small, single-center study of 14 children, so the results may not apply broadly. Rehabilitation programs can be time-consuming and may not show measurable benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

14 people

The number who actually took part.

Started

Jun 2024

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 10 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient participant Eligibility Criteria: Inclusion Criteria: * Genetically confirmed SMA considered as a non-sitter, sitter or walker * Post-symptomatically treated and on stable dose for 12 months with any disease-modifying market-approved drug * Patients from 1-10 years of age at baseline * Parent(s)/legal guardian(s) of patients less than 16 years of age must provide written informed consent prior to the patient's participation in the study * Willing and able to comply with all protocol requirements and procedures. Exclusion Criteria: The participant may not enter the trial if ANY of the following apply: * Any acute or chronic condition which, as assessed by the investigator, significantly interferes with the rehabilitation of the patient * Need of diurnal and/or invasive ventilation, naps excluded * Currently enrolled in a treatment study; or treatment with an experimental therapy * Any surgical and/or medical intervention, according to the investigator, 3 months before baseline and/or during the study participation. Carer (considered as participant) Eligibility Criteria: Inclusion Criteria: * Willing and able to comply with all protocol requirements and procedures * Carer's child has been included in study. Exclusion Criteria: • No exclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spinal muscular atrophy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

spinal muscular atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spinal muscular atrophy

Contacts and locations

Locations

  • Oxford Brookes University

    Oxford, Oxfordshire, OX3 0BP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.